Intraoperative Use of Topical Retropharyngeal Steroids for Dysphagia after Anterior Cervical Fusion: A Systematic Review and Meta-Analysis

Hang Yu, Hui Dong, Binjia Ruan, Xiaohang Xu, and Yongxiang Wang

1Clinical Medical College of Yangzhou University, Yangzhou, China
2Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China
3The Yangzhou School of Clinical Medicine of Dalian Medical University, Yangzhou, China

Correspondence should be addressed to Yongxiang Wang; wyx918spine@126.com

Received 4 November 2021; Accepted 14 December 2021; Published 31 December 2021

Academic Editor: Wen-Jun Tu

Copyright © 2021 Hang Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The anterior cervical approach is commonly used clinically for cervical spondylosis, but it also results in frequent postoperative dysphagia, which can increase the risk of complications and poor treatment satisfaction in severe cases. Intraoperative local application of retropharyngeal steroids has an impact on reducing the occurrence and severity of dysphagia; however, the results of current studies vary. The meta-analysis of this randomized trial was to evaluate the effectiveness and safety of intraoperative topical retropharyngeal steroids for the control of dysphagia after anterior cervical spine surgery.

Methods. Two authors searched electronic databases such as PubMed, MEDLINE, EMBASE, Cochrane Library, and Google Scholar, respectively. The search terms were “Dysphagia,” “Steroids,” “Anterior Cervical Discectomy and Fusion,” etc. A random effects model was used to conduct a meta-analysis based on deviance information criteria. Results. A total of 8 studies were included in this meta-analysis after screening of 792 studies. Bazaz scores were not significantly different in the steroid group at one day postoperatively ($P = 0.38$), and dysphagia was significantly improved at 14 days postoperatively (95% CI: 0.15 to 0.64; $P = 0.002$). PSTSI was significantly improved one day ($P = 0.03$) and 14 days after surgery ($P < 0.0001$). VAS scores were all lower versus controls ($P < 0.001$). Conclusion. Perioperative local retropharyngeal steroid administration as an adjunct to anterior cervical spine surgery reduces the incidence and severity of dysphagia compared with placebo control. However, future high-quality randomized controlled studies could incorporate nonsubjective dysphagia measures and long-term follow-up on the occurrence of associated complications or other side effects.

1. Introduction

The current standard approach for the treatment of cervical disc disease is anterior cervical spinal fusion (ACDF) using the Smith-Robinson technique. This approach is considered relatively safe and effective; however, it has been reported to be associated with complications such as dysphagia, airway damage, and vocal disturbances in up to 79% of patients [1–3]. Although the exact pathophysiological mechanism of dysphagia after anterior cervical spine surgery is not fully understood, some studies have been proposed that it may be the effect of local soft-tissue edema, paralysis of the recurrent laryngeal nerve, or prevertebral soft-tissue swelling (PSTS) [4–6]. Severe dysphagia after ACDF has been demonstrated to lead to malnutrition, aspiration, increased risk of pulmonary complications, and increased medical costs [7].

To reduce the incidence and severity of dysphagia, steroids are often used in clinical practice. Corticosteroids are known anti-inflammatory agents that inhibit the production of inflammatory prostaglandins and cytokines. This inflammatory process is responsible for the swelling of the soft tissues, which eventually leads to compression of the esophagus and trachea. Several studies have shown that the use of systemic corticosteroids after anterior cervical spine surgery is beneficial in reducing the incidence and severity of dysphagia [8–10]. While these results are encouraging,
systemic administration of corticosteroids is also associated with systemic side effects; this may be a limitation of this route of administration. For this reason, the efficacy of topical application of corticosteroids to the retropharyngeal space for anterior cervical fusion has been investigated. However, the reported results are not the same [11, 12], and the association between local application of corticosteroids on postoperative tissue swelling and dysphagia has not been well described. Therefore, to provide clear and uniform conclusions using the best available evidence, a systematic review and meta-analysis of randomized controlled trials was conducted. The primary and secondary objectives of this study were to determine whether the intraoperative application of topical corticosteroids in anterior cervical surgery has substantial clinical benefit in reducing the severity of dysphagia and identify any clinically relevant complications associated with corticosteroid therapy.

2. Materials and Methods

The study was conducted following the guidelines outlined in the PRISMA (preferred reporting items for systematic reviews and meta-analysis) statement [13]. The data included in this study are from published studies and are not directly relevant to the patients. Therefore, ethics committee approval and informed consent were not required.

2.1. Identification of Studies. A comprehensive literature search was conducted, to identify all published studies evaluating the efficacy of topical applied corticosteroids for anterior cervical fusion. Two independent reviewers conducted a systematic electronic search of PubMed, MEDLINE, EMBASE, the Cochrane Library, and Google Scholar. The search date is from the beginning to June 31, 2021. The keywords used for the search are “Dysphagia,” “Deglutition Disorders,” “Swallowing Disorders,” “Steroids,” “Cervical Vertebrae,” “Anterior Cervical Discectomy and Fusion,” “ACDF” and their near synonyms, etc. There are no restrictions based on publication date, language, or follow-up.

2.2. Assessment of Eligibility. The following criteria were used for study inclusion: (1) adult patients with cervical spondylosis undergoing single- or multilevel anterior decompression-only fusion; (2) perioperative topical corticosteroids, placebo in the control group, and no other interventions for dysphagia; and (3) RCT design.

The exclusion criteria are as follows: (1) trials that explicitly include cases of trauma, tumor, or infection; (2) abstracts, letters, or conference proceedings; and (3) studies for which no extractable data are available.

2.3. Selection of Literature. It was filtered by scanning the titles of each study to filter out inappropriate articles. An independent reviewer then reviewed the abstracts of the remaining studies and selected those that were potentially relevant to our study. Two authors independently reviewed the full text of these articles as well as the references for additional research. We then critically evaluated the studies according to the inclusion and exclusion criteria and assessed the quality of the randomized controlled trials according to the suggested checklist. All differences were resolved by consensus through discussion and further confirmed by a third author.

2.4. Assessment of Risk of Bias and Data Extraction. Study quality was assessed using version 2 of the Cochrane Risk of Bias Tool for Randomized Trials (RoB 2). Two reviewers applied all criteria to each study independently, using a uniform methodology. Clinical outcome data from individual studies were independently extracted into spreadsheets by 2 reviewers and reviewed against the original information to avoid errors. Data extracted from the study included identifiers, study characteristics, patient demographics, interventions, surgical data, perioperative PSTS, clinical dysphagia outcomes, visual analog scale (VAS), and complications, and disagreements were resolved through discussion and negotiation. PSTS is measured as the ratio of the measured anterior soft-tissue thickness of the vertebral body to the anterior-posterior (AP) diameter of each vertebral body.

To compare the overall PSTS of the two groups, the mean PSTS at C3, 4, and 5 where edema was observed to be most pronounced was defined as the prevertebral soft-tissue swelling index (PSTSI). PSTSI eliminates interindividual differences, such as vertebral width or any other abnormalities in the cervical or retropharyngeal space, facilitating comparisons with other postoperative patients as well as with the patients themselves [14, 15].

2.5. Statistical Analysis. The meta-analysis was analyzed using Review Manager 5.3 (RevMan 5.3. Ink, Cochrane Collaboration, Oxford, United Kingdom). The I² statistic (ranging from 0 to 100%) was used to quantify the heterogeneity between studies. I² values >50% indicate significant heterogeneity, and random effects analysis was used to compare heterogeneous results. There is likely to be a high degree of heterogeneity between different randomized controlled trials due to clinical and methodological factors. Thus, even if I² is small, the random effects model is applicable to the entire meta-analysis. Continuous variables are reported as mean differences and 95% confidence intervals, such as time to surgery, and dichotomous variables (e.g., complications) are reported as risk ratios and 95% confidence intervals; P value < 0.05 was considered to indicate a significant difference. Funnel plots were performed to assess publication bias.

3. Results

3.1. Search Results. The flowchart of the search is shown in Figure 1. The search yielded 792 studies, of which 39 were duplicates. 742 studies were excluded based on title, abstract, and full-text screening, leaving 12 possible articles. Three other studies were excluded after full-text review because they did not use topical steroids or were not RCTs. Of the nine articles included, all were eligible for the meta-analysis. These studies included a total of 632 patients, of which 327 constituted the topical steroid group and the placebo group consisted of the remaining 305 patients. Table 1 summarizes the characteristics of the eight included articles.
3.2. Risk of Bias. The Cochrane risk of bias assessment for RCTs is shown in Figure 2. Two studies were found to have a “high” risk of bias, primarily attributable to the randomization process and outcome measures. For all studies, we used the modified Jadad scale to evaluate the qualities of them, where 3-5 scores mean high quality and 0-2 scores mean low quality. For quality assessment, all studies included in our research were of high quality [22] (Table 2).

3.3. Primary Outcome. In this series, the most commonly used tool for assessing dysphagia is the Bazaz scale [20, 21, 23] or its modified version, the Modified Dysphagia Scoring System (MDSS) [18, 19]. The Bazaz scale and MDSS have 4 levels: none, mild, moderate, and severe. Meta-analysis of the Bazaz scale of dysphagia showed no significant difference on the postoperative day \( (P = 0.38) \); however, at 2 weeks postoperatively, the overall incidence and severity of dysphagia were significantly lower in the patients in the topical steroid group than in the control group \( (P = 0.002) \) (Figure 3). Meta-analysis showed statistically significantly lower PSTSI in the topical steroid group than in the control group both one day after surgery and 2 weeks after surgery \( (1 \text{ day}, P = 0.03 \text{ and 2 weeks}, P < 0.0001) \) (Figure 4).

3.4. Secondary Outcome. A total of five studies reported VAS scores at the follow-up time points. VAS scores were significantly lower in the topical steroid group than in the control group one day postoperatively \( (I^2 = 38\%, P < 0.0001) \) versus 2 weeks postoperatively \( (I^2 = 72\%, P = 0.002) \) (Figure 5).

3.5. Publication Bias and Sensitivity Analysis. We performed funnel plotting of the postoperative Bazaz score as well as the PSTSI, and the funnel plot shows a symmetric distribution (Figures 6 and 7). Although the statistical power was limited by the total number of studies, no significant bias was found.

To determine the effect of each study on postoperative Bazaz scores, postoperative PSTSI, and VAS scores, we perform a sensitivity analysis to verify the robustness of our results. No significant effect on the results was observed after excluding any single study, suggesting that the results of this meta-analysis are relatively robust.

4. Discussion

ACDF is an effective treatment for degenerative cervical spine disease when nonsurgical treatment has failed. Despite the clinical success of ACDF, postoperative problems may arise that the most common is dysphagia, the prevalence of which can be as high as 79%. Our meta-analysis of 632 patients in eight randomized trials found that topical steroids significantly reduced the occurrence and severity of dysphagia and improved neck pain after ACDF surgery. This is similar to the results of two previous systematic reviews and a meta-analysis [24–26]; they support the use of steroids to prevent dysphagia in patients undergoing anterior cervical fusion surgery. However, they included studies that also included systemic intravenous application of steroid hormones. Considering that topically applied steroids have a lower risk of systemic reactions or complications, our study compared the efficacy of topical steroid application with placebo control only. However, on the first postoperative day, there was no significant difference in the incidence of dysphagia between the two groups of patients. It is likely that the initial dysphagia on the first postoperative day is more of a mechanistic effect caused by the inherent manipulation of the esophagus by surgery [19], rather than due to swelling or inflammation, as the swelling of the anterior neck tissue gradually increases in the days following the procedure. And the topical application of steroids is a combination of steroids with gelatin sponges, which may delay the distribution and action of the drug, thus preventing any apparent effect on the first postoperative day [17]. There are no
studies examining the exact pharmacokinetics of this route and method of administration [16].

The prevertebral soft tissues observed on a lateral radiograph consist of the muscles, ligaments, and cervical fascia of the pharynx or esophagus. Dissecting and stretching them during ACDF, edematous and inflammatory changes occur which leads to muscle and subperiosteal hemorrhage and soft-tissue swelling, resulting in the development of PSTS [27]. Dysphagia is common after ACDF surgery, and several studies have shown that the occurrence and severity of postoperative dysphagia are related to the degree of PSTS. Related reports indicate that the most severe PSTS occurs around the C4 vertebral body [14], and this is consistent with the findings of Suk et al. Therefore, the mean value of PSTSI at C3, 4, and 5 (PSTSI) was used as the standardized comparison parameter. This meta-analysis found that topical steroid hormone application reduced the degree of PSTSI in patients on the first postoperative day, and at the second postoperative week, the PSTSI values were significantly lower in the steroid group compared to the control group. The incidence of painful dysphagia immediately after surgery was significantly lower in the steroid group than in the control group, and recovery was also faster; this is attributed to the control of the local inflammatory response by steroids and the subsequent reduction of the PSTS effect.

Esophageal perforation, one of the most dreaded complications of ACDF, has an incidence of 0.02% to 1.52% [28]. Topical steroids, on the other hand, increase the chance of perforation because they may reduce the ability of soft tissues to heal on their own. Only one study in this analysis reported 2 cases of delayed esophageal perforation [11]; they cautioned against the use of topical retropharyngeal steroids in patients with a long history of chronic steroid application.

Corticosteroids reduce inflammation by decreasing neutrophil adhesion to the vascular endothelium and inhibit macrophages by limiting chemotaxis, phagocytosis, and cytokine release. However, while steroids suppress inflammation, they also increase the risk of infection. Dahapute et al.’s study

Table 1: Baseline characteristics of studies included in the systematic review.

| Study (year)       | Experimental data | Control data | Outcomes recorded | Follow-up (month) |
|--------------------|-------------------|--------------|-------------------|-------------------|
| Dahapute 2020 [15] | 25 50.4 76 25 | 50.4 76 | PSTS, VAS, NDI | 12 |
| Ryan 2021 [16]     | 37 59 41 36 | 57 50 | Bazaz, EAT-10 | 3 |
| Kim 2021 [17]      | 56 58.1 48.2 53 | 58.4 54.7 | EAT-10, SWAL-QOL, VAS, NDI | 1 |
| Haws 2018 [12]     | 55 49.4 56.4 49 | 50.6 61.2 | PSTS, SWAL-QOL, VAS | 3 |
| Jekins 2018 [18]   | 29 55.6 51.7 21 | 54 52.3 | Bazaz, EAT-10, VAS neck pain, NDI | 12 |
| Edwards 2016 [19]  | 27 54 41 23 | 54.5 39 | Modified Dysphagia Scoring System | 1 |
| Lee 2011 [11]      | 25 54.3 72 25 | 50.9 56 | PSTS, VAS, NDI | 22 |
| Seddighi 2017 [20] | 38 49.3 47.3 38 | 50.2 42.1 | Bazaz, PSTS, VAS | 6 |
| Grasso 2019 [21]   | 35 46.1 51.4 35 | 45.5 48.5 | Bazaz, VAS | 12 |

Figure 2: Risk-of-bias assessment.
showed that there were no significant differences in postoperative inflammatory indicators of white blood cell count and CPR between the two groups, and one case of infection was reported in the placebo group. Corticosteroids can promote apoptosis of osteoblasts and bone cells, which may affect bone healing as well as increase the risk of prosthetic joints. In this meta-analysis, although some studies reported cases of postoperative pseudarthrosis, but at subsequent follow-up, there were signs of bone nonunion in both groups, while excluding the possibility of a significant effect of steroids on bone healing [15]. However, this result should be interpreted with caution, because two of the eight studies did not report infection rates and four did not report pseudarthrosis rates. It is possible that the distant adverse effects and complications of steroids were not captured due to the short follow-up period.

The current study observed some limitations. Given the variation in the types and doses of steroids used in each study, we are unable to provide information on the best treatment regimen for reducing the rate and severity of postoperative dysphagia after ACDF, and better treatment doses may exist. We suggest that a relevant randomized controlled trial could be conducted to find the best clinical treatment option to reduce postoperative dysphagia using different types and different doses of topical steroids. Currently, one of the challenges in evaluating dysphagia is that there is no...
and day 14. Figure 6 Disease Markers for some of the studies, which may have biased the results. dysphagia measure, so comparable data were not available studies took different outcome scores for the postoperative dysphagia measure, and more invasive modalities such as barium swallow tests and video laryngeal endoscopy can eliminate this subjective factor. In addition, the greatest change in dysphagia severity in the included study population appeared to occur in the first 2 weeks postoperatively. However, incidence and severity were measured only a small number of times during this period, thus obscuring the exact onset and duration of postoperative dysphagia that may be reduced by topical steroids in patients undergoing ACDF surgery. In the included studies, the short- to medium-term follow-up may have missed the time

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|------------------|----|-------|-------------|----|-------|--------|-----------------------------------|-----------------------------------|
| 2.1.1 PTSTI PO1   |                  |    |       |              |    |       |        |                                   |                                   |
| Dahapute 2020     | 0.61 0.067       | 25 | 0.65 0.067 | 25 | 34.5 % |        | -0.04 [-0.08, -0.00]               |                                   |
| Lee 2011          | 0.58 0.19        | 25 | 0.74 0.19 | 25 | 5.6 % |        | -0.16 [-0.27, -0.05]               |                                   |
| Seddighi 2017     | 0.69 0.31        | 38 | 0.83 0.31 | 38 | 3.2 % |        | -0.14 [-0.28, -0.00]               |                                   |
| Subtotal (95 % CI)| 88 88            |     | 43.3 % | 43.3 %      |       |      |        | -0.10 [-0.19, -0.01]               |                                   |
| Heterogeneity: Tau² = 0.00; Chi² = 5.83, df = 2 (p = 0.05); I² = 66 % |
| Test for overall effect: Z = 2.17 (p = 0.03) |

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|------------------|----|-------|-------------|----|-------|--------|-----------------------------------|-----------------------------------|
| 2.1.2 PTSTI PO14  |                  |    |       |              |    |       |        |                                   |                                   |
| Dahapute 2020     | 0.48 0.13        | 25 | 0.57 0.13 | 25 | 11.3 % |        | -0.09 [-0.16, -0.02]               |                                   |
| Haws 2018         | 0.78 0.18        | 55 | 0.86 0.16 | 49 | 13.5 % |        | -0.08 [-0.15, -0.01]               |                                   |
| Lee 2011          | 0.45 0.11        | 25 | 0.51 0.11 | 25 | 15.3 % |        | -0.06 [-0.12, -0.00]               |                                   |
| Seddighi 2017     | 0.58 0.13        | 38 | 0.64 0.13 | 38 | 16.5 % |        | -0.06 [-0.12, -0.00]               |                                   |
| Subtotal (95 % CI)| 143 137         |     | 56.7 % | 56.7 %      |       |      |        | -0.07 [-0.10, -0.04]               |                                   |
| Heterogeneity: Tau² = 0.00; Chi² = 6.70, df = 6 (p = 0.35); I² = 10 % |
| Test for overall effect: Z = 5.20 (p < 0.00001) |
| Test for subgroup differences: Chi² = 0.34, df = 1 (p = 0.56). I² = 0 % |

**Figure 4:** PTSTI was significantly different in the steroid group on the first postoperative day and on postoperative day 14.

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|------------------|----|-------|-------------|----|-------|--------|-----------------------------------|-----------------------------------|
| 3.1.1 VAS PO1     |                  |    |       |              |    |       |        |                                   |                                   |
| Dahapute 2020     | 7.28 1.25        | 25 | 8.52 1.25 | 25 | 14.5 % |        | -0.24 [-1.93, -0.55]               |                                   |
| Grasso 2019       | 6.28 35          | 35 | 6.28 35 | 35 | 3.7 % |        | -3.00 [-5.94, -0.06]               |                                   |
| Jenkins 2018      | 6.296 29         | 29 | 7.185 29 | 21 | 9.9 % | -1.00 [-2.34, -0.34]               |                                   |
| Lee 2011          | 2.5 2.82         | 25 | 5.3 2.82 | 25 | 8.5 % |        | -2.80 [-4.36, -1.24]               |                                   |
| Seddighi 2017     | 2.9 5.89         | 38 | 6.2 5.89 | 38 | 4.3 % |        | -3.30 [-5.95, -0.65]               |                                   |
| Subtotal (95 % CI)| 152 144         |     | 40.8 % | 40.8 %      |       |      |        | -1.80 [-2.66, -0.94]               |                                   |
| Heterogeneity: Tau² = 0.35; Chi² = 6.68, df = 4 (p = 0.17); I² = 38 % |
| Test for overall effect: Z = 4.10 (p < 0.00001) |

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|------------------|----|-------|-------------|----|-------|--------|-----------------------------------|-----------------------------------|
| 3.1.2 VAS PO14    |                  |    |       |              |    |       |        |                                   |                                   |
| Dahapute 2020     | 0.28 0.47        | 25 | 0.8 0.47 | 25 | 17.1 % |        | -0.52 [-0.78, -0.26]               |                                   |
| Grasso 2019       | 3.2 6.28         | 35 | 6.2 6.28 | 35 | 3.7 % |        | -3.00 [-5.94, -0.06]               |                                   |
| Haws 2018         | 3.2 2.5          | 55 | 3.5 2.5 | 49 | 12.5 % |        | -0.20 [-1.16, -0.76]               |                                   |
| Jenkins 2018      | 4.222 29         | 29 | 6.22 29 | 21 | 10.4 % | -2.00 [-3.25, -0.75]               |                                   |
| Lee 2011          | 1.2 2.32         | 25 | 3.5 2.32 | 25 | 10.2 % | -2.30 [-3.59, -1.01]               |                                   |
| Seddighi 2017     | 1.4 5.1          | 38 | 3.9 5.1 | 38 | 5.3 % |        | -2.50 [-4.79, -0.21]               |                                   |
| Subtotal (95 % CI)| 207 193         |     | 59.2 % | 59.2 %      |       |      |        | -1.38 [-2.25, -0.51]               |                                   |
| Heterogeneity: Tau² = 0.69; Chi² = 17.57, df = 5 (p = 0.004); I² = 72 % |
| Test for overall effect: Z = 3.12 (p = 0.002) |

**Figure 5:** Secondary outcome VAS scores was significantly lower in the steroid group than in the control group on both postoperative day 1 and day 14.

“gold standard” outcome indicator. Therefore, the included studies took different outcome scores for the postoperative dysphagia measure, so comparable data were not available for some of the studies, which may have biased the results. Also, differences in the design, definition, and outcome measures of studies of postoperative dysphagia in ACDF may be one reason for the wide variation in reported prevalence. Although relevant patient-centered dysphagia questionnaires and indicators have been validated, there is a subjective component to patient response, and more invasive modalities such as barium swallow tests and video laryngeal endoscopy can eliminate this subjective factor. In addition, the greatest change in dysphagia severity in the included study population appeared to occur in the first 2 weeks postoperatively. However, incidence and severity were measured only a small number of times during this period, thus obscuring the exact onset and duration of postoperative dysphagia that may be reduced by topical steroids in patients undergoing ACDF surgery. In the included studies, the short- to medium-term follow-up may have missed the time
to maximum benefit for patients, as well as long-term outcome indicators, including fusion rates. However, we can say with confidence that the use of topically applied steroids is effective and does not significantly increase the risk of complications. But the differences between the included studies make it difficult to provide clear and specific recommendations. Therefore, future studies could include nonsubjective measures of dysphagia, more frequent documentation of patient-reported dysphagia, larger study populations, subgroup analyses, and cost-effectiveness analyses of intraoperative steroid use to reduce dysphagia after ACDF surgery.

5. Conclusion

This meta-analysis found moderate-quality evidence supporting perioperative topical steroid administration as an
adjunct to anterior cervical spine surgery to reduce the incidence and severity of dysphagia compared with placebo. Future high-quality randomized comparative effectiveness trials are assured.

**Abbreviations**

ACDF: Anterior cervical spinal fusion  
PSTS: Prevertebral soft-tissue swelling  
PSTSI: Prevertebral soft-tissue swelling index  
MDSS: Modified Dysphagia Scoring System.

**Data Availability**

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

**Conflicts of Interest**

The authors have no relevant financial or nonfinancial interests to disclose.

**Authors’ Contributions**

Hang Yu and Hui Dong contributed equally to this work and should be considered as co-first authors. Hang Yu contributed to research design, acquisition of data, analysis and interpretation of data, and writing—original draft. Hui Dong contributed to acquisition of data, analysis and interpretation of data, and writing—original draft. Binjia Ruan and Xiaohang Xu contributed to acquisition of data, analysis and interpretation of data, and methodology. Yongxiang Wang contributed to conceptualization, research design, revision, and supervision.

**Acknowledgments**

This study was supported by the National Natural Science Foundation of China (82072423).

**References**

[1] C. A. Smith-Hammond, K. C. New, R. Pietrobon, D. J. Curtis, C. H. Scharver, and D. A. Turner, “Prospective analysis of incidence and risk factors of dysphagia in spine surgery patients: comparison of anterior cervical, posterior cervical, and lumbar procedures [J],” *Spine (Phila Pa 1976)*, vol. 29, no. 13, pp. 1441–1446, 2004.

[2] K. K. Anderson and P. M. Arnold, “Oropharyngeal dysphagia after anterior cervical spine surgery: a review [J],” *Global Spine J.*, vol. 3, no. 4, pp. 273–285, 2013.

[3] P. G. Campbell, S. Yadla, J. Malone et al., “Early complications related to approach in cervical spine surgery: single-center prospective study [J],” *World Neurosurgery*, vol. 74, no. 2-3, pp. 363–368, 2010.

[4] N. Nagoshi, L. Tetreault, H. Nakashima et al., “Risk factors for and clinical outcomes of dysphagia after anterior cervical surgery for degenerative cervical myelopathy: results from the AOSpine International and North America Studies [J],” *The Journal of Bone and Joint Surgery. American Volume*, vol. 99, no. 13, pp. 1069–1077, 2017.

[5] M. J. Lee, R. Bazaz, C. G. Furey, and J. Yoo, “Risk factors for dysphagia after anterior cervical spine surgery: a two-year prospective cohort study [J],” *The Spine Journal*, vol. 7, no. 2, pp. 141–147, 2007.

[6] L. H. Riley 3rd, R. L. Skolasky, T. J. Albert, A. R. Vaccaro, and J. G. Heller, “Dysphagia after anterior cervical decompression and Fusion,” *Spine (Phila Pa 1976)*, vol. 30, no. 22, pp. 2564–2569, 2005.

[7] H. M. Starmer, L. H. Riley 3rd, A. T. Hillel, L. M. Akst, S. R. A. Best, and C. G. Gourin, “Dysphagia, short-term outcomes, and cost of care after anterior cervical disc surgery,” *Dysphagia*, vol. 29, no. 1, pp. 68–77, 2014.

[8] K. J. Song, S. K. Lee, J. H. Ko, M. J. Yoo, D. Y. Kim, and K. B. Lee, “The clinical efficacy of short-term steroid treatment in multilevel anterior cervical arthrodesis [J],” *The Spine Journal*, vol. 14, no. 12, pp. 2954–2958, 2014.

[9] S. B. Jayamohan, T. J. Kenning, K. A. Petronis, P. J. Feustel, D. Drazin, and D. J. DiRisio, ”Effect of steroid use in anterior cervical discectomy and fusion: a randomized controlled trial [J],” *Journal of Neurosurgery. Spine*, vol. 23, no. 2, pp. 137–143, 2015.

[10] M. Pedram, L. Castagnera, X. Carat, G. Macouillard, and J. M. Vital, “Pharyngolaryngeal lesions in patients undergoing cervical spine surgery through the anterior approach: contribution of methylprednisolone [J],” *European Spine Journal*, vol. 12, no. 1, pp. 84–90, 2003.

[11] S. H. Lee, K. T. Kim, K. S. Suk, K. J. Park, and K. I. Oh, “Effect of retropharyngeal steroid on prevertebral soft tissue swelling following anterior cervical discectomy and fusion: a prospective, randomized study [J],” *Spine (Phila Pa 1976)*, vol. 36, no. 26, pp. 2286–2292, 2011.

[12] B. E. Haws, B. Khechen, A. S. Narain et al., “Impact of local steroid application on dysphagia following an anterior cervical discectomy and fusion: results of a prospective, randomized single-blind trial [J],” *Journal of Neurosurgery. Spine*, vol. 29, no. 1, pp. 10–17, 2018.

[13] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [J],” *International Journal of Surgery*, vol. 8, no. 5, pp. 336–341, 2010.

[14] K. S. Suk, K. T. Kim, S. H. Lee, and S. W. Park, “Prevertebral soft tissue swelling after anterior cervical discectomy and fusion with plate fixation [J],” *International Orthopaedics*, vol. 30, no. 4, pp. 290–294, 2006.

[15] A. Dahapute, S. Sonone, S. Bhaladhave et al., “Prospective randomized controlled trial to study the effect of local steroids in the retropharyngeal space after anterior cervical discectomy and fusion [J],” *Global Spine J.*, vol. 11, no. 6, pp. 826–832, 2021.

[16] R. A. Cutro and C. C. Edwards, “Does local steroid reduce dysphagia after cervical disc replacement? A prospective, randomized, placebo-controlled, double-blinded study [J],” *Clin Spine Surg*, vol. 34, no. 6, pp. E329–E336, 2021.

[17] H. J. Kim, R. Alluri, D. Stein et al., “Effect of topical steroid on swallowing following ACDF: results of a prospective double-blind randomized control trial [J],” *Spine (Phila Pa 1976)*, vol. 46, no. 7, pp. 413–420, 2021.

[18] T. J. Jenkins, R. Nair, S. Bhatt et al., “The effect of local versus intravenous corticosteroids on the likelihood of dysphagia and
dysphonia following anterior cervical discectomy and fusion: a single-blinded, prospective, randomized controlled trial [J],” *The Journal of Bone and Joint Surgery. American Volume*, vol. 100, no. 17, pp. 1461–1472, 2018.

[19] C. C. Edwards, C. Dean, C. C. Edwards, D. Phillips, and A. Blight, “Can dysphagia following anterior cervical fusions with rhBMP-2 be reduced with local depomedrol Application?,” *Spine*, vol. 41, no. 7, pp. 555–562, 2016.

[20] M. Hasani Barzi, M. Nikoobakht, N. Hasani Barzi, F. Khanali, and Z. Yazdi, “Effect of local steroid injection on prevertebral soft tissue swelling following anterior cervical discectomy and fusion [J],” *International Clinical Neuroscience Journal*, vol. 4, no. 3, pp. 84–90, 2017.

[21] G. Grasso, L. Leone, and F. Torregrossa, “Dysphagia prevention in anterior cervical disectomy surgery: results from a prospective clinical study [J],” *World Neurosurgery*, vol. 125, p. e1176, 2019.

[22] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J],” *Controlled Clinical Trials*, vol. 17, no. 1, pp. 1–12, 1996.

[23] R. Bazaz, M. J. Lee, and J. U. Yoo, “Incidence of dysphagia after anterior cervical spine surgery - a prospective study [J],” *Spine*, vol. 27, no. 22, pp. 2453–2458, 2002.

[24] J. W. Liu, Y. Q. Zhang, Y. Hai, N. Kang, and B. Han, “Intravenous and local steroid use in the management of dysphagia after anterior cervical spine surgery: a systematic review of prospective randomized controlled trails (RCTs) [J],” *European Spine Journal*, vol. 28, no. 2, pp. 308–316, 2019.

[25] S. A. Zadegan, S. B. Jazayeri, A. Abedi, H. N. Bonaki, A. R. Vaccaro, and V. Rahimi-Movaghar, “Corticosteroid administration to prevent complications of anterior cervical spine fusion: a systematic review [J],” *Global Spine J*, vol. 8, no. 3, pp. 286–302, 2018.

[26] S. Garcia, N. E. Schafer, N. Wallace, B. B. Butt, J. Gagnier, and I. S. Aleem, “Perioperative corticosteroids reduce dysphagia severity following anterior cervical spinal fusion: a meta-analysis of randomized controlled trials [J],” *The Journal of Bone and Joint Surgery. American Volume*, vol. 103, no. 9, pp. 821–828, 2021.

[27] A. Frempong-Boadu, J. K. Houten, B. Osborn et al., “Swallowing and speech dysfunction in patients undergoing anterior cervical discectomy and fusion: a prospective, objective preoperative and postoperative assessment [J],” *Journal of Spinal Disorders & Techniques*, vol. 15, no. 5, pp. 362–368, 2002.

[28] S. H. Halani, G. R. Baum, J. P. Riley et al., “Esophageal perforation after anterior cervical spine surgery: a systematic review of the literature [J],” *Journal of Neurosurgery. Spine*, vol. 25, no. 3, pp. 285–291, 2016.